How many 8-K filings has Soleno Therapeutics Inc filed?

Soleno Therapeutics Inc (SLNO) has 31 8-K (Current Event Report) filings on record, spanning Jan 2024 to Apr 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Soleno Therapeutics Inc 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Soleno Therapeutics Inc 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Soleno Therapeutics Inc (SLNO) — 8-K Filings

All 8-K filings from Soleno Therapeutics Inc. Browse 31 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (31)

Soleno Therapeutics Files 8-K Report — Apr 7, 2026 Risk: low
On April 7, 2026, Soleno Therapeutics Inc. filed an 8-K report detailing other events. The filing does not contain specific financial figures or new material ev
Soleno Therapeutics Files Material Definitive Agreement — Apr 6, 2026 Risk: medium
On April 6, 2026, Soleno Therapeutics Inc. filed an 8-K report detailing a material definitive agreement. The filing includes exhibits such as the agreement its
Soleno Therapeutics Enters Material Agreement, Creates Financial Obligation — Nov 12, 2025 Risk: medium
On November 10, 2025, Soleno Therapeutics, Inc. entered into a material definitive agreement, likely related to financing or a significant business transaction.
Solen Therapeutics Reports Director Changes and Compensation Adjustments — Oct 14, 2025 Risk: medium
Solen Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting on the departure of a director, election of a new director, and changes in officer compensa
Soleno Therapeutics Files 8-K — Sep 10, 2025 Risk: low
On September 10, 2025, Soleno Therapeutics, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, meaning it contains material information
Soleno Therapeutics Files 8-K — Aug 18, 2025 Risk: low
On August 18, 2025, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
Soleno Therapeutics Files 8-K — Aug 6, 2025 Risk: low
On August 6, 2025, Soleno Therapeutics, Inc. filed an 8-K report. The filing indicates the company's fiscal year ends on December 31st. Soleno Therapeutics, for
Soleno Therapeutics Enters Material Definitive Agreement — Jul 11, 2025 Risk: medium
On July 10, 2025, Soleno Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements
Soleno Therapeutics Files 8-K on Operations — Jul 10, 2025 Risk: low
On July 10, 2025, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
Soleno Therapeutics Files 8-K on Security Holder Vote Matters — Jun 6, 2025 Risk: low
On June 5, 2025, Soleno Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of its security holders. The filing does not specify
Soleno Therapeutics Files 8-K on Operations and Financials — May 7, 2025 Risk: low
On May 7, 2025, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as wel
Soleno Therapeutics Changes Independent Auditor — Apr 18, 2025 Risk: low
On April 17, 2025, Soleno Therapeutics, Inc. filed an 8-K report to disclose a change in its certifying accountant. The company has appointed PricewaterhouseCoo
Soleno Therapeutics Files 8-K on Financials — Mar 26, 2025 Risk: low
On March 26, 2025, Soleno Therapeutics, Inc. filed an 8-K report detailing its financial condition and results of operations. The company, formerly known as Cap
Soleno Therapeutics Files 8-K on Financials — Feb 27, 2025 Risk: low
On February 27, 2025, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
Soleno Therapeutics Announces Board and Executive Changes — Jan 24, 2025 Risk: medium
On January 21, 2025, Soleno Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The fili
Soleno Therapeutics Enters Material Definitive Agreement — Dec 17, 2024 Risk: medium
On December 17, 2024, Soleno Therapeutics, Inc. entered into a material definitive agreement, likely related to its financial obligations. The company, formerly
Soleno Therapeutics Files 8-K — Nov 26, 2024 Risk: low
On November 26, 2024, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine updat
Soleno Therapeutics Files 8-K on Financials — Nov 6, 2024 Risk: low
On November 6, 2024, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, a
Soleno Therapeutics Appoints New Chief Medical Officer — Aug 15, 2024 Risk: medium
On August 9, 2024, Soleno Therapeutics, Inc. announced the appointment of Dr. Jonathan M. G. Farquharson as Chief Medical Officer. Dr. Farquharson brings extens
Soleno Therapeutics Files 8-K on Operations — Aug 7, 2024 Risk: low
On August 7, 2024, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, alo
Solen Therapeutics Adds Directors, Adjusts Executive Pay — Jul 19, 2024 Risk: medium
Solen Therapeutics, Inc. announced on July 17, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the company elect
Soleno Therapeutics Closes $100M Public Offering — Jun 28, 2024 Risk: medium
On June 28, 2024, Soleno Therapeutics, Inc. filed an 8-K report detailing the closing of its previously announced underwritten public offering. The company succ
Soleno Therapeutics Secures $50M Credit Facility — Jun 20, 2024 Risk: medium
On June 13, 2024, Soleno Therapeutics, Inc. entered into a Material Definitive Agreement, specifically a Second Amendment to the Second Amended and Restated Cre
Soleno Therapeutics Files 8-K on Security Holder Vote Matters — Jun 6, 2024 Risk: low
On June 6, 2024, Soleno Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as C
Soleno Therapeutics Files 8-K on Financials — May 10, 2024 Risk: low
On May 9, 2024, Soleno Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The company, formerly known as Capnia, Inc., is in
Soleno Therapeutics Files 8-K: Material Agreement & Other Events — May 7, 2024 Risk: medium
On May 2, 2024, Soleno Therapeutics, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed within the filing. The company also
Soleno Therapeutics Merges with Altacell, Renamed ATCL — Apr 29, 2024 Risk: medium
On April 29, 2024, Soleno Therapeutics, Inc. filed an 8-K report detailing the completion of its merger with Altacell, Inc. The merger was approved by Soleno's
Soleno Therapeutics Appoints New CMO and CSO, CMO Departs — Apr 22, 2024 Risk: medium
On April 17, 2024, Soleno Therapeutics, Inc. announced the appointment of Dr. Jonathan M. Geller as Chief Medical Officer and Dr. David M. D. Smith as Chief Sci
Soleno Therapeutics Files 8-K on Financials — Mar 7, 2024 Risk: low
On March 6, 2024, Soleno Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The company, formerly known as Capnia, Inc., is
SOLENO THERAPEUTICS 8-K: Leadership & Compensation Changes Reported — Jan 30, 2024
SOLENO THERAPEUTICS INC filed an 8-K on January 30, 2024, reporting an event that occurred on January 24, 2024. This filing indicates changes related to the dep
SOLENO THERAPEUTICS Reports Executive Changes & Compensation on Jan 4 — Jan 5, 2024
SOLENO THERAPEUTICS INC filed an 8-K on January 4, 2024, to report a 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX